We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Therapeutic Opportunities in Microplastic- and Nanoplastic-Associated Neuroinflammation A Mechanism-Guided Analysis of Drug Development, Repurposing, and New-Indication Opportunities
Summary
Tiny plastic particles from our environment may get into the body and trigger inflammation, stress on cells, and disruption of the protective barrier around the brain, though scientists still need more research to confirm exactly how this affects human health. This review maps out these possible biological pathways not just to understand the risk, but to spot opportunities for treatments, including testing existing drugs that already target similar processes in other diseases. The bigger takeaway: even without all the answers yet, understanding how microplastics might affect the brain could help researchers develop therapies faster by building on drugs we already have.
Microplastics and nanoplastics (MPs/NPs) can interact with biological systems through multiple mechanisms that may affect the central nervous system, including immune activation, blood-brain barrier dysfunction, oxidative stress, mitochondrial dysfunction, cytokine signaling, disrupted autophagy/proteostasis, neuronal injury, and gut-brain axis disruption. These pathways are biologically plausible, but links to human disease remain incomplete and require further study. From a therapeutic-development perspective, the key question is whether characterizing MP/NP-associated pathology can reveal actionable biological pathways. This creates opportunities for novel targets (where coverage is limited), drug repurposing (where existing agents already target the pathway), and indication expansion (where MP/NP-derived insights apply to other diseases sharing the same pathway). We outline a preliminary mechanism-guided landscape of MP/NP-associated neuroinflammatory biology and a framework for identifying these opportunities. Based on this analysis, Cythera Bio has prioritized two pathways for initial investigation, with others still under evaluation.